Pharmacological treatment of obesity

Psychiatric Annals

Volumn 41, Issue 10, 2011, Pages 489-495

  Tek, Cenk ^a   Ratliff, Joseph C ^a   Chwastiak, Lydia ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054827287     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20110921-08     Document Type: Article

References (24)

1. Jeffery RW, Wing RR, Thorson C, et al. Strengthening behavioral interventions for weight loss: a randomized trial of food provision and monetary incentives. J Consult Clin Psychol. 1993;61(6):1038-1045.
2. Wadden TA, Butryn ML, Byrne KJ. Effi cacy of lifestyle modifi cation for long-term weight control. Obes Res. 2004;12 Suppl:151S-162S.
3. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefi ts of lifestyle modifi cation in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001;161(2):218-227.
4. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfl uramine phentermine. N Eng J Med. 1997;337(9):581-588.
5. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546.
6. Food and Drug Administration, HHS. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist. 2004;69(28):6787-6854.
7. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Guidance for Industry. Developing Products for Weight Management. Draft. 2007.
8. Allison DB, Mentore JL, Heo M, et al. Antipsychotic- induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696.
9. Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: Results from the national health and nutrition examination survey. Obesity. 2010;18(12):2398-2400.
10. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med. 2002;346(6):393-403.
11. Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med. 2005;142(1):56-66.
12. Morgenthaler TI, Silber MH. Amnestic sleeprelated eating disorder associated with zolpidem. Sleep Med. 2002;3(4):323-327.
13. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007;132(6):2239-2252.
14. Fujimoto WY, Jablonski KA, Bray GA, et al. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes. 2007;56(6):1680-1685.
15. Mafong DD, Henry RR. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep. 2008;10(1):55-60.
16. Greenway FL, Dunayevich E, Tollefson G, et al; NB-201 Study Group. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94(12):4898-4906.
17. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
18. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
19. Gadde KM, Yonish GM, Foust MS, Wagner II HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: A preliminary, randomized, open-label study. J Clin Psychiatry. 2007;68(8):1226-1229.
20. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Eng J Med. 2010;363(3):245-256.
21. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: metaanalysis of randomized trials. Int J Obes Relat Metab Disord. 2003;27(4):522-529.
22. Whelan AM, Jurgens TM, Szeto V. Case report. Efficacy of Hoodia for weight loss: is there evidence to support the effi cacy claims? J Clin Pharm Ther. 2010;35(5):609-612.
23. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;40(2):187-200.
24. Jean-Baptiste M, Tek C, Liskov E, et al. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res. 2007;96(1-3):198-205.